FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892295086> ?p ?o ?g. }

• W2892295086 endingPage "32" @default.
• W2892295086 startingPage "26" @default.
• W2892295086 abstract "PurposeTo evaluate long-term tolerability, safety and efficacy of adjunctive perampanel in a Phase II, multicentre, open-label, dose-ascending Study 231 (NCT00849212) and its extension (Study 233; NCT00903786) in Japanese patients with refractory partial-onset seizures (POS), with/without secondarily generalised seizures.MethodsIn Study 231, patients received adjunctive perampanel ≤12 mg/day during a 10-week treatment period. Patients completing Study 231 could enter Study 233 (≤316-week treatment period). Assessments included monitoring of treatment-related treatment-emergent adverse events (TEAEs), median percent change in seizure frequency per 28 days, 50% responder and seizure-freedom rates. During Study 231, a pharmacokinetic analysis assessed the effects of enzyme-inducing antiepileptic drugs.ResultsOverall, 23/30 (76.7%) patients completed Study 231; 21/30 (70.0%) received perampanel ≥8 mg/day and 10/30 (33.3%) achieved a maximum tolerated dose of 12 mg/day. Median percent change in seizure frequency per 28 days was –35.0%. 50% responder rate was 37.0%; 4 (13.3%) patients achieved seizure freedom. Twenty-one patients entered Study 233. Mean duration of exposure was 195 weeks; 9 (42.9%) patients received perampanel for ≤208 weeks. Seizure control was sustained for 316 weeks in 3/21 (14.3%) patients; 2 achieved seizure freedom. Treatment-related TEAEs were tolerable; the most common was dizziness (Study 231, 53.3%; Study 233, 14.3%). Mean perampanel plasma concentrations were lower with concomitant carbamazepine vs non-inducers (152.7 ng/mL vs 389.4 ng/mL across perampanel groups); small patient numbers for non-inducers (n = 2) should be considered when interpreting these data.ConclusionAdjunctive perampanel demonstrated a favourable safety profile and long-term tolerability in Japanese patients with refractory POS for ≤316 weeks." @default.
• W2892295086 created "2018-09-27" @default.
• W2892295086 creator A5014364578 @default.
• W2892295086 creator A5017658555 @default.
• W2892295086 creator A5023502731 @default.
• W2892295086 creator A5035588431 @default.
• W2892295086 creator A5039128309 @default.
• W2892295086 creator A5040411174 @default.
• W2892295086 creator A5045525134 @default.
• W2892295086 creator A5058255287 @default.
• W2892295086 creator A5082610939 @default.
• W2892295086 date "2018-11-01" @default.
• W2892295086 modified "2023-10-01" @default.
• W2892295086 title "Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy" @default.
• W2892295086 cites W1498758291 @default.
• W2892295086 cites W1546717111 @default.
• W2892295086 cites W1551373999 @default.
• W2892295086 cites W1944765057 @default.
• W2892295086 cites W1970988925 @default.
• W2892295086 cites W1978437325 @default.
• W2892295086 cites W1983656228 @default.
• W2892295086 cites W1989054396 @default.
• W2892295086 cites W2023205599 @default.
• W2892295086 cites W2035775274 @default.
• W2892295086 cites W2047168413 @default.
• W2892295086 cites W2071065489 @default.
• W2892295086 cites W2083402697 @default.
• W2892295086 cites W2089791879 @default.
• W2892295086 cites W2090025584 @default.
• W2892295086 cites W2090276138 @default.
• W2892295086 cites W2105535280 @default.
• W2892295086 cites W2117821603 @default.
• W2892295086 cites W2124847836 @default.
• W2892295086 cites W2132146185 @default.
• W2892295086 cites W2132499662 @default.
• W2892295086 cites W2135808877 @default.
• W2892295086 cites W2140614993 @default.
• W2892295086 cites W2145546535 @default.
• W2892295086 cites W2161208527 @default.
• W2892295086 cites W2163482216 @default.
• W2892295086 cites W2217932554 @default.
• W2892295086 cites W2288518629 @default.
• W2892295086 cites W2769648968 @default.
• W2892295086 cites W2772236704 @default.
• W2892295086 cites W4236676256 @default.
• W2892295086 cites W4248307879 @default.
• W2892295086 doi "https://doi.org/10.1016/j.seizure.2018.09.012" @default.
• W2892295086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30267941" @default.
• W2892295086 hasPublicationYear "2018" @default.
• W2892295086 type Work @default.
• W2892295086 sameAs 2892295086 @default.
• W2892295086 citedByCount "13" @default.
• W2892295086 countsByYear W28922950862019 @default.
• W2892295086 countsByYear W28922950862020 @default.
• W2892295086 countsByYear W28922950862021 @default.
• W2892295086 countsByYear W28922950862022 @default.
• W2892295086 countsByYear W28922950862023 @default.
• W2892295086 crossrefType "journal-article" @default.
• W2892295086 hasAuthorship W2892295086A5014364578 @default.
• W2892295086 hasAuthorship W2892295086A5017658555 @default.
• W2892295086 hasAuthorship W2892295086A5023502731 @default.
• W2892295086 hasAuthorship W2892295086A5035588431 @default.
• W2892295086 hasAuthorship W2892295086A5039128309 @default.
• W2892295086 hasAuthorship W2892295086A5040411174 @default.
• W2892295086 hasAuthorship W2892295086A5045525134 @default.
• W2892295086 hasAuthorship W2892295086A5058255287 @default.
• W2892295086 hasAuthorship W2892295086A5082610939 @default.
• W2892295086 hasBestOaLocation W28922950861 @default.
• W2892295086 hasConcept C118552586 @default.
• W2892295086 hasConcept C126322002 @default.
• W2892295086 hasConcept C197934379 @default.
• W2892295086 hasConcept C2778186239 @default.
• W2892295086 hasConcept C2778375690 @default.
• W2892295086 hasConcept C2779253243 @default.
• W2892295086 hasConcept C2779384505 @default.
• W2892295086 hasConcept C2780836401 @default.
• W2892295086 hasConcept C3018162438 @default.
• W2892295086 hasConcept C42219234 @default.
• W2892295086 hasConcept C71924100 @default.
• W2892295086 hasConceptScore W2892295086C118552586 @default.
• W2892295086 hasConceptScore W2892295086C126322002 @default.
• W2892295086 hasConceptScore W2892295086C197934379 @default.
• W2892295086 hasConceptScore W2892295086C2778186239 @default.
• W2892295086 hasConceptScore W2892295086C2778375690 @default.
• W2892295086 hasConceptScore W2892295086C2779253243 @default.
• W2892295086 hasConceptScore W2892295086C2779384505 @default.
• W2892295086 hasConceptScore W2892295086C2780836401 @default.
• W2892295086 hasConceptScore W2892295086C3018162438 @default.
• W2892295086 hasConceptScore W2892295086C42219234 @default.
• W2892295086 hasConceptScore W2892295086C71924100 @default.
• W2892295086 hasLocation W28922950861 @default.
• W2892295086 hasLocation W28922950862 @default.
• W2892295086 hasOpenAccess W2892295086 @default.
• W2892295086 hasPrimaryLocation W28922950861 @default.
• W2892295086 hasRelatedWork W2078972332 @default.
• W2892295086 hasRelatedWork W2132146185 @default.
• W2892295086 hasRelatedWork W2755222529 @default.
• W2892295086 hasRelatedWork W2774229355 @default.

• next